Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization for res

Systematic review of the side effects associated with tyrosine kinase inhibitors used in the treatment of gastrointestinal stromal tumours on behalf of the EORTC Quality of Life Group

(2014) Samantha C. Sodergren et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Cost-effectiveness of pazopanib in advanced soft-tissue sarcoma in Canada

(2014) T.E. Delea et al.   Current Oncology

Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic review

(2013) Sheetal Sharma et al.   BMC CANCER

Reporting of Patient-Reported Outcomes in Randomized Trials

(2013) Melanie Calvert et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma

(2013) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Normative Data of the EORTC QLQ-C30 For the German Population: A Population-Based Survey

(2013) Annika Waldmann et al.   PLoS One

Pazopanib

(2012) Emma D. Deeks   DRUGS

Pazopanib in the treatment of soft tissue sarcoma

(2012) Patrick Schöffski   Expert Review of Anticancer Therapy

Antiangiogenic therapy for advanced renal cell carcinoma: Management of treatment-related toxicities

(2012) Roger B. Cohen et al.   INVESTIGATIONAL NEW DRUGS

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

(2012) Winette TA van der Graaf et al.   LANCET

Elicitation of health state utilities in soft tissue sarcoma

(2012) Sarah L. Shingler et al.   QUALITY OF LIFE RESEARCH

Histology-Driven Chemotherapy in Soft Tissue Sarcomas

(2011) Michelle Scurr   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial

(2011) D. Cella et al.   EUROPEAN JOURNAL OF CANCER

Compartmental resection for subfascial extremity soft tissue sarcoma and quality of life in long-term survivors

(2011) Matthias Peiper et al.   WIENER KLINISCHE WOCHENSCHRIFT

Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)

(2009) Stefan Sleijfer et al.   JOURNAL OF CLINICAL ONCOLOGY

Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials

(2009) Chantal Quinten et al.   LANCET ONCOLOGY

Angiogenesis Inhibition in Non-GIST Soft Tissue Sarcomas

(2008) S. Sleijfer et al.   ONCOLOGIST